HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Albuminuria is associated with an increased prostasin in urine while aldosterone has no direct effect on urine and kidney tissue abundance of prostasin.

Abstract
The proteinase prostasin is a candidate mediator for aldosterone-driven proteolytic activation of the epithelial sodium channel (ENaC). It was hypothesized that the aldosterone-mineralocorticoid receptor (MR) pathway stimulates prostasin abundance in kidney and urine. Prostasin was measured in plasma and urine from type 2 diabetic patients with resistant hypertension (n = 112) randomized to spironolactone/placebo in a clinical trial. Prostasin protein level was assessed by immunoblotting in (1) human and rat urines with/without nephrotic syndrome, (2) human nephrectomy tissue, (3) urine and kidney from aldosterone synthase-deficient (AS-/-) mice and ANGII- and aldosterone-infused mice, and in (4) kidney from adrenalectomized rats. Serum aldosterone concentration related to prostasin concentration in urine but not in plasma. Plasma prostasin concentration increased significantly after spironolactone compared to control. Urinary prostasin and albumin related directly and were reduced by spironolactone. In patients with nephrotic syndrome, urinary prostasin protein was elevated compared to controls. In rat nephrosis, proteinuria coincided with increased urinary prostasin, unchanged kidney tissue prostasin, and decreased plasma prostasin while plasma aldosterone was suppressed. Prostasin protein abundance in human nephrectomy tissue was similar across gender and ANGII inhibition regimens. Prostasin urine abundance was not different in AS-/- and aldosterone-infused mice. Prostasin kidney level was not different from control in adrenalectomized rats and AS-/- mice. We found no evidence for a direct relationship between mineralocorticoid receptor signaling and kidney and urine prostasin abundance. The reduction of urinary prostasin in spironolactone-treated patients is most likely the result of an improved glomerular filtration barrier function and generally reduced proteinuria.
AuthorsChristina Oxlund, Birgül Kurt, Ilona Schwarzensteiner, Mie R Hansen, Mette Stæhr, Per Svenningsen, Ib A Jacobsen, Pernille B Hansen, Anne D Thuesen, Anja Toft, Gitte R Hinrichs, Claus Bistrup, Boye L Jensen
JournalPflugers Archiv : European journal of physiology (Pflugers Arch) Vol. 469 Issue 5-6 Pg. 655-667 (06 2017) ISSN: 1432-2013 [Electronic] Germany
PMID28233126 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Antihypertensive Agents
  • Spironolactone
  • Aldosterone
  • Serine Endopeptidases
  • prostasin
Topics
  • Adult
  • Aged
  • Albuminuria (blood, etiology, urine)
  • Aldosterone (blood)
  • Animals
  • Antihypertensive Agents (adverse effects, pharmacology, therapeutic use)
  • Diabetic Nephropathies (complications)
  • Female
  • Humans
  • Hypertension (complications, drug therapy)
  • Kidney (drug effects, metabolism)
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Middle Aged
  • Rats
  • Rats, Sprague-Dawley
  • Serine Endopeptidases (blood, metabolism, urine)
  • Spironolactone (adverse effects, pharmacology, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: